---
title: "Ersodetug (RZ358) in Tumor hyperinsulinism: Pharmacokinetics"
description: "Formulary evidence on Ersodetug (RZ358) in Tumor hyperinsulinism: Pharmacokinetics. Topics: Absorption, half-life, accumulation, and steady state: healthy volunteers and congenital hyperinsulinism; Single-dose half-life: healthy volunteers; Half-life and potential for monthly dosing; Repeat-dose pharmacokinetics: congenital hyperinsulinism. 4 evidence topics quoted from 5 sources."
canonical: "https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description/pharmacokinetics"
published: "2026-11-15T20:24:18-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Ersodetug (RZ358) in Tumor hyperinsulinism: Pharmacokinetics

<a id="heading-2.1.2.6.3"></a>

## 2.1.2.6.3 Pharmacokinetics

<a id="topic-2.1.2.6.3-1"></a>

### Absorption, half-life, accumulation, and steady state: healthy volunteers and congenital hyperinsulinism

> “In healthy volunteers and individuals with congenital HI, ersodetug displays dose-proportional pharmacokinetics after intravenous administration, with peak serum concentrations observed within approximately 2 hours, an effective half-life of about 15 days (terminal elimination half-life 15-28 days), modest accumulation with repeat dosing, and concentrations that are predicted to approach or exceed 90% of steady-state within roughly 4-8 weeks depending on dosing frequency, with steady-state generally achieved by about 12 weeks.”

Source: [Strosberg et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671785/)

<a id="topic-2.1.2.6.3-2"></a>

### Single-dose half-life: healthy volunteers

> “X358 exhibited dose-proportional PK with a half-life of 21 days.”

Source: [Johnson et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28605468/)

<a id="topic-2.1.2.6.3-3"></a>

### Half-life and potential for monthly dosing

> “Ersodetug shows dose dependent pharmacokinetics with a half-life greater than 2 weeks, which has the potential for monthly dosing.”

Source: [Rezolute Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926110420/rzlt-20260630x10k.htm)

<a id="topic-2.1.2.6.3-4"></a>

### Repeat-dose pharmacokinetics: congenital hyperinsulinism

> “Ersodetug resulted in predictable, dose-proportional pharmacokinetics.”

Source: [Demirbilek et al. (2025)](https://www.cell.com/med/fulltext/S2666-6340(25)00038-8)

Additional sources: [ClinicalTrials.gov NCT04538989](https://clinicaltrials.gov/study/NCT04538989)

## Related pages
- [Ersodetug (RZ358): Tumor hyperinsulinism](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Terms and abbreviations](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/terms-and-abbreviations.md)
- [Ersodetug (RZ358): Tumor hyperinsulinism](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/executive-summary.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Product information and disease description](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Clinical evidence](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/clinical-evidence.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Economic information and modeling report](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/economics) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/economics.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: References](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/references) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/references.md)
